MoonLake Immunotherapeutics (MLTX) Misses Q2 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Guggenheim on 'Best Idea' Moonlake Immunotherapeutics (MLTX): 'We Continue To Anticipate Highly Positive Pivotal HS Readout Around Sept (2H)'
August 5, 2025 12:26 PM EDTGuggenheim analyst Yatin Suneja reiterated a Buy rating and $80.00 price target on Moonlake Immunotherapeutics (NASDAQ: MLTX).
The analyst comments "Key Message: Our key takeaways from MLTX's 2Q25 release are: (1) Highly-anticipated Phase III VELA results that evaluate sonelokimab (SLK; small nanobody with dual IL-17A/F targeting) in hidradenitis suppurativa (HS) remain on-track for "around" September. Last patient, last visit has occurred in VELA-2; VELA-1 is on-track to complete in August. Assuming ~4-6 weeks of data analysis, we think data are likely... More
